期刊文献+

2008-2009年鲍氏不动杆菌临床分布与耐药性分析 被引量:3

Distribution and drug resistance of acinetobacter baumannii from 2008 to 2009
原文传递
导出
摘要 目的分析2008-2009年鲍氏不动杆菌临床分布及耐药性变化,为临床合理使用抗菌药物提供依据。方法收集临床分离的鲍氏不动杆菌,采用Microscan全自动微生物分析仪进行细菌的鉴定及药敏试验,部分药敏试验采用K-B法,应用WHONET 5软件统计数据。结果 2008年鲍氏不动杆菌的分离率为5.33%,2009年鲍氏不动杆菌的分离率为10.41%(P<0.05);痰标本为鲍氏不动杆菌的主要标本来源,ICU为主要病区;2008年除头孢哌酮/舒巴坦、美罗培南、亚胺培南的耐药率<5.00%之外,对其他测试药物耐药率均>25.00%,并呈现多药耐药;2009年所有测试药物的耐药率均大幅上升,显著高于2008年(P<0.05),亚胺培南的耐药率为52.81%,美罗培南的耐药率为40.55%,头孢哌酮/舒巴坦的耐药率为38.53%,其余测试药物耐药率均>50.00%,呈现严重的多药耐药;2008年泛耐药鲍氏不动杆菌(PDR-ABA)的比例为2.94%,2009年PDR-ABA的比例骤然上升至30.16%(P<0.05)。结论鲍氏不动杆菌的分离率及耐药性呈明显上升趋势,耐药形势异常严峻,需引起医院各部门的高度关注。 OBJECTIVE To analyze the distribution and drug resistance of Acinetobacter baumannii from 2008 to 2009,provide the basis for clinical antibiotics application.METHODS The A.baumannii strains isolated from clinical samples were collected,the identification and antimicrobial susceptibility test were determined by Microscan automatic of microorganism identification and antimicrobial susceptibility testing system,some susceptibility tests adopt the Kirby-Bauer method,the data was analyzed by WHONET 5 sofeware.RESULTS The isolating rate of A.baumannii was 5.33% in 2008,the isolating rate of A.baumannii was 10.41% in 2009,(P0.05).Sputum was the main specimen sources,and ICU was the main endemic area.In 2008,the drug resistance rate of cefoperazone/sulbactam,meropenem and imipenem was below of 5.00%,the drug resistance rate of other drugs exceeded 25.00%,and presented multidrug-resistance.In 2009,the resistance rate of the isolates was significantly exceeded those of isolates in 2008,(P0.05).The drug resistance rate to imipenem was 52.81%,the drug resistance rate of meropenem was 40.55%,the drug resistance rate of cefoperazone/sulbactam was 38.53%,the drug resistance rate of other drugs exceeded 50.00%,and presented severe multidrug-resistance.The rate of PDR-ABA was 2.94% in 2008,and the rate of PDR-ABA was 30.16%,(P0.05).CONCLUSION The isolated rate and drug resistant rate of A.baumannii present obviously ascendant tendency,and the rate of PDR-ABA was 30.16% in 2009.The situation is very severe,every department of hospital should pay more attentions to the problems.
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2011年第8期1677-1679,共3页 Chinese Journal of Nosocomiology
关键词 鲍氏不动杆菌 抗菌药物 耐药性 Acinetobacter baumannii Antibacterials Drug resistance
  • 相关文献

参考文献9

  • 1苏兆亮,糜祖煌,孙光明,陈建国,郑东,刘嫣方,Sandoghchian Siamak,许化溪.多药耐药鲍氏不动杆菌耐药性与转座子及插入序列遗传标记研究[J].中华医院感染学杂志,2010,20(20):3085-3087. 被引量:113
  • 2肖永红,王进,赵彩云,高磊,郑波,薛峰,李湘艳,郝凤兰,代表Mohnarin协作组.2006-2007年Mohnarin细菌耐药监测[J].中华医院感染学杂志,2008,18(8):1051-1056. 被引量:607
  • 3覃金爱,郭世辉,朱莲娜,梁宏洁,农加根,钟品玲,韦惠茹.682株鲍曼不动杆菌分布及耐药性分析[J].中国感染控制杂志,2009,8(5):356-357. 被引量:10
  • 4张晓兵,龚雅利,刘智勇,府伟灵.鲍氏不动杆菌的临床分布特征及耐药趋势分析[J].中华医院感染学杂志,2008,18(3):428-430. 被引量:88
  • 5Halstead DC, Abid J, Dowzicky MJ. Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumarmii complex and Enterobacteriaceae collected as part of the tigecycline evaluation and surveillance trial[J]. J Intect,2007,55(1) :49-57.
  • 6Rafailidis PI, Ioannidou EN, Falagas ME. Ampicillin/sulbactam: current status in severe bacterial infection[J]. Drugs, 2007,67(13) : 1829-1849.
  • 7Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections [J]. lancet Infect Dis,2008,8(12) ,751-762.
  • 8Gales AC,Jones RN,Sader HS. Global assessment of the an timicrobial activity of polymyein B against 54 731 clinical iso lares of Gram-negative bacilli : report from the SENTRY anti microbial surveillance programme(2001-2004)[J]. Clin Mi erobiol Infect,2006,12(4):315-321.
  • 9Peleg AY, Seifert H ,Paterson DL. Acinetobacter baumannii : emergence of a successful pathogen[J]. Clin Microbiol Rev, 2008, (3) : 538-582.

二级参考文献34

共引文献805

同被引文献37

  • 1卢健聪,蔡绍曦,耿穗娜,佟万成,马真,孟莹,刘来昱.下呼吸道感染患者中分离鲍曼不动杆菌的耐药性分析[J].中国感染与化疗杂志,2009,9(1):60-62. 被引量:19
  • 2胡志东,田彬,徐海茹,李琴,钟述猷.临床患者分离的鲍氏不动杆菌耐药性分析[J].中华医院感染学杂志,2005,15(1):112-114. 被引量:57
  • 3张樱,陈亚岗,杨青.不动杆菌感染及耐药机制的研究进展[J].国外医学(流行病学.传染病学分册),2005,32(2):109-112. 被引量:93
  • 4王辉,陈民钧,倪语星,陈冬梅,孙自庸,陈燕,赵旺胜,邹雄,俞云松,胡志东,黄心宏,徐英春,谢秀丽,褚云卓,王倩,梅亚宁,田彬,张蓓,孔庆莲,于秀娟,潘玉红.2003—2004年中国十家教学医院革兰阴性杆菌的耐药分析[J].中华检验医学杂志,2005,28(12):1295-1303. 被引量:236
  • 5石岩,刘大为,许大波,徐英春,陈民均,王辉.泛耐药鲍曼不动杆菌感染临床治疗初探[J].中国感染与化疗杂志,2007,7(1):34-37. 被引量:112
  • 6Falagas ME,Bliziotis IA,Siempos II.Attributable mortalityof Acinetobacter baumannii infections in critically ill patients:a systematic review of matched cohort and case-control stud-ies[J].Crit Care,2006,10(2):R48.
  • 7Gales AC,Jones RN,Sader HS.Global assessment of theantimicrobial activity of polymyxin B against 54 731clinical i-solates of gram-negative bacilli:report from the SENTRY an-timicrobial surveillance programme(2001-2004)[J].ClinMicrobiol Infect,2006,12(4):315-321.
  • 8Falagas ME,Kasiakou SK.Colistin:the revival of polymyx-ins for the management of multidrug-resistant gram-negativebacterial infections[J].Clin Infect Dis,2005,40(9):1333-1341.
  • 9American Thoracic Society,Infectious Diseases Society of A-merica.Guidelines for the management of adults with hospital-acquired,ventilator-associated,and healthcare-associatedpneumonia[J].Am J Respir Crit Care Med,2005,171(4):388-416.
  • 10Halstead DC,Abid J,Dowzicky MJ.Antimicrobial suscepti-bility among Acinetobacter calcoaceticus-baumannii complexand Enterobacteriaceae collected as part of the Tigecycline E-valuation and Surveillance Trial[J].J Infect,2007,5(1):49-57.

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部